Fortitude Biomedicines (NASDAQ: FBIO) Advances Dual-Target T Cell Therapy for Axial Spondyloarthritis
Key Developments Fortitude Biomedicines (NASDAQ: FBIO) has unveiled a pioneering dual-specific antibody that targets T cells for the treatment of axial spondyloarthritis (AxSpA), marking a significant step forward in addressing this chronic inflammatory condition. This therapy aims to modulate disease-driving T cell signaling pathways implicated in AxSpA, offering a novel approach for patients suffering from this debilitating disease. In addition, Fortitude Biomedicines has appointed Dr. Rahul Patel, a Fellow of…
